Risperidone controlled-release implant - Braeburn Pharmaceuticals

Drug Profile

Risperidone controlled-release implant - Braeburn Pharmaceuticals

Alternative Names: BB0817; EN 3342

Latest Information Update: 17 May 2016

Price : $50

At a glance

  • Originator Endo Pharmaceuticals
  • Developer Braeburn Pharmaceuticals
  • Class Antineoplastics; Antipsychotics; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Schizophrenia

Most Recent Events

  • 01 Apr 2016 Phase-III clinical trials in Schizophrenia in USA (SC) (NCT02773576)
  • 01 Oct 2015 Phase-II clinical trials in Schizophrenia in USA (SC) (NCT02658357)
  • 01 May 2015 Braeburn Pharmaceuticals acquires Risperidone controlled-release implant from Endo Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top